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Abstract
Substantial recent experimental evidence has demonstrated the existence of reciprocal
interactions between the microvascular bed of a specific organ and intravascular metastatic tumor
cells through expression of adhesion molecules and nitric oxide release, resulting in a significant
impact upon metastatic outcomes.
This review summarizes the current findings of adhesive and cytotoxic endothelial-tumor cell
interactions in the liver, the inducibility, zonal distribution and sinusoidal structural influences on
the hepatic endothelial regulatory functions, and the effects of these functions on the formation of
liver cancer metastases. New insights into the traditional cancer metastatic cascade are also
discussed.
Introduction
The formation of a metastatic tumor in the secondary
organ is the result of dissemination of a primary cancer
cell, survival in the circulation, passing through the vascu-
lar bed in the distant organ and cancer cell proliferation
[1-4]. Cancer metastasis is known to be an inefficient
process, which reflects the fact that most of the intravascu-
lar cancer cells are killed within blood vessels or lym-
phatic channels [5,6]. Metastasis is accomplished in a
step-wise or metachronous fashion [6,7]. More recent
studies using mouse and rat models and in vivo video
microscopy have demonstrated that the initial steps of the
haematogenous metastatic process, from cancer cells
entering the bloodstream to extravasating into secondary
organs, are completed with remarkable efficiency [8,9].
The inefficiency is more associated with the subsequent
steps involving cell division and formation of microme-
tastases by extravasated cancer cells in the secondary site
[7,8,10]. In contrast, other studies have indicated that the
majority of disseminating tumor cells die rapidly in the
blood circulation and can not pass the first capillary bed
they encounter [8,11-13]. With the metastatic cascade
being well-outlined in the literature, the specific underly-
ing mechanisms of tumor cell loss in the circulation and
secondary organs, and the determinant factors for metas-
tases formation still remain to be fully elucidated
[3,10,14].
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Recent in vivo and in vitro experimental evidence from var-
ious laboratories strongly suggests that, during the interac-
tions between an organ microvascular bed and
intravascular tumor cells, nitric oxide (NO) plays a signif-
icant role as a cytotoxic natural defensive effector, pro-
duced by the vascular endothelial cells, to exert toxic
effects on invading tumor cells, interact with endothelial
adhesion molecules and regulate the subsequent meta-
static tumor formation in the secondary organ [10,15,16].
This review surveys this new evidence and reviews current
opinions derived mostly from animal studies on how
endothelial and tumor cells interact with each other
through adhesive and cytotoxic properties in the hepatic
microvascular bed. We describe how these interactions
and metastases formation can be influenced by sinusoidal
structural and functional characteristics and alterations.
The identification of this host internal defensive mecha-
nism gives new insights into cancer metastatic ineffi-
ciency, and identifies a new barrier in the classic model of
the cancer metastatic cascade.
Influence of hepatic adhesive properties
Endothelial-tumor cell interactions are regulated by 
inducible adhesion molecules expressed in the liver
Since the "seed and soil" theory proposed by Stephen
Paget, there has been a long history of research into the
reasons for organ-specific cancer metastasis [17,18]. The
liver is a common site for metastasis of human cancer and
a convenient target for experimental studies of metastasis.
From the latter it is apparent that endothelial cell surface
adhesion molecules have an extensive role in regulating
cancer cell site-specific arrest, transendothelial migration
and metastases formation [3,19-23].
Expression of various hepatic endothelial adhesion mole-
cules has been demonstrated to be selectively inducible by
cytokines, bacterial lipopolysaccharide (LPS) or arresting
tumor cells in the liver microvascular bed. In turn, these
adhesion molecules can be shown to regulate the arrest of
circulating cancer cells in the hepatic sinusoids. For exam-
ple, interleukin-1α (IL-1α) pretreatment of mice altered
the melanoma cell (B16F1) arrest pattern from 32 µm
beyond the sinusoidal inlet to larger terminal portal
venules (TPV) observed by intravital videomicroscopy,
suggesting increased adhesive interactions between
endothelial and tumor cells following IL-1α stimulation
[24]. Interleukin-18 (IL-18) has been demonstrated in vivo
and  in vitro to promote liver metastasis by enhancing
melanoma cell adhesion to the hepatic sinusoidal
endothelial cells via microvascular VCAM-1 (vascular cell
adhesion molecule-1) expression [25-27]. With a basal
expression level of ICAM-1 (intercellular adhesion mole-
cule-1), minimal expression of VCAM-1 and no expres-
sion of E-selectin or αv integrin in unstimulated mouse
livers, 1 µg/g body weight of LPS i.p. selectively induced
the expression of ICAM-1 (4–48 h), VCAM-1 (4–24 h)
and E-selectin (2 h) on the sinusoidal lining cell surface,
while αv integrin expression was unchanged [28,29]. LPS
did not significantly alter the expression of VLA-4 (very
late antigen-4, counter receptor of VCAM-1) or LFA-1
(leukocyte functional antigen-1, counter receptor of
ICAM-1) on melanoma cells either in vivo or in vitro [30].
Tumor necrosis factor (TNF) induced sustained VCAM-1
expression within 4 h in the lung, liver and kidney of mice
[31], and increased the adhesion of highly metastatic
murine carcinoma cell line H-59, and human colorectal
carcinoma lines HM 7 and CX-1 to murine hepatic
endothelial cells in the primary culture. This effect was
completely abolished by a monoclonal antibody to
murine E-selectin [21]. Mannose receptor-mediated
endothelial cell activation also contributed to B16
melanoma cell adhesion and metastasis in the mouse
liver [32].
The expression of sinusoidal adhesion molecules is
affected by metastatic cells in the hepatic microenviron-
ment. The arrest of B16F1 melanoma cells in the liver
sinusoids (following mesenteric vein injection) induced
focal expression of VCAM-1 and more diffuse expression
of ICAM-1 around the melanoma cell arrest sites [30].
Similarly, the arrest of murine carcinoma line H-59 cells
after intrasplenic injection induced E-selectin expression
on the hepatic sinusoidal endothelium between 2–24 h
[33]. The expression of ICAM-1, VCAM-1, E-selectin and
αv integrin was all induced to different degrees by the
growth of melanoma tumors in the peritoneal cavity with-
out liver metastasis in the mouse [28]. In a study on pro-
gression of mouse melanoma (B16-BL6) spontaneous
metastasis, organ specific induction of VCAM-1 was
observed in the cardiac, hepatic and cerebral vascular beds
4 weeks following the resection of primary tumors when
metastatic pulmonary burden was maximal [34]. Intras-
plenically injected B16 melanoma (B16M) cells also
increased the expression of VCAM-1 significantly on
hepatic sinusoidal endothelial cells within the first 24 h,
which correlated with the increased in vitro adhesion of
B16M cells to hepatic sinusoidal endothelial cells isolated
from B16M cell-injected mice [35].
The mechanisms and significance of the selectivity of
adhesion molecule induction have not been fully
described at this stage. However, the inducibility of vari-
ous adhesion molecules on the hepatic endothelial cell
surface by different microenvironmental stimuli has pro-
vided a potential diversity and flexibility for sinusoidal
endothelial cells to participate in tumor defensive
responses when intravascular metastatic cancer cells are
present.Comparative Hepatology 2005, 4:8 http://www.comparative-hepatology.com/content/4/1/8
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Impact of sinusoidal structural and functional 
characteristics on adhesion molecule induction
The micro-structural and functional heterogeneity in the
liver across its functional unit of acinar zonation has been
well-described in the literature [36-39]. This hepatic zonal
heterogeneity has also played a significant role influenc-
ing the patterns of induced adhesion molecule expression.
Differential zonal expressions of certain adhesion mole-
cules induced by LPS stimulation have been demon-
strated [28]. With a weak expression around the terminal
portal venule regions (acinar zone 1) under basal condi-
tions, ICAM-1 was induced to a uniform strong expression
(4–48 h) across each entire acinus in the liver following
LPS administration. On the contrary, VCAM-1 and E-
selectin both had minimal or no expression in unstimu-
lated livers, but had significantly stronger expression in
acinar zone 1 than zone 2 and 3 after LPS stimulation,
with VCAM-1 expressed between 4–48 h and E-selectin 2–
12 h [28]. LPS stimulation also increased the retention of
B16F1 melanoma cells in the liver between 8–24 h, espe-
cially in the terminal portal venule region presumably
through increased expression of adhesion molecules,
ICAM-1 and VCAM-1 [30]. IL-1 zonal heterogeneity of
mannose receptor-mediated ligand endocytosis in the
mouse and rat liver was also observed using flow cytome-
try following LPS stimulation [40,41]. In human studies,
major differences have been noted in the composition of
the portal tract and sinusoid with regard to endothelial
and parenchymal cell expression of cell-cell and cell-
matrix adhesion molecules during inflammatory reac-
tions in human liver grafts [42]. Differential expression of
various adhesion molecules has been reported between
normal and inflamed livers, or livers rejected after trans-
plantation in humans. The selectins ELAM-1 (endothelial
leukocyte adhesion molecule) and CD62 (cluster of dif-
ferentiation 62) were basally expressed and inducible on
portal tract endothelia and central vein endothelia with
acute and chronic human liver inflammation, although
sinusoidal endothelia lack this mechanism even with
severe inflammation [43]. Portal and sinusoidal endothe-
lia showed a different expression and inducibility of
VCAM-1, ICAM-1, ICAM-2, and LFA-3 (leukocyte func-
tional antigen-3) in human livers [43].
In addition to the impact of hepatic zonal heterogeneity
on adhesion molecule expression, alterations in the liver
sinusoidal architecture also significantly change the
endothelial cell surface molecule expression and tumor
cell behavior patterns. Using a murine liver cirrhosis
model, where the sinusoidal lumens were narrowed due
to the formation of fibrous tissue, the expression of adhe-
sion molecules ICAM-1 and VCAM-1 was found to be sig-
nificantly increased (stronger in acinar zone 1) on the
endothelial surface with E-selectin undetectable [44].
After injecting melanoma cells into the portal vein,
melanoma cell retention in the cirrhotic liver terminal
portal venule regions was also significantly increased in
comparison with the control livers [44].
Influence of hepatic cytotoxic properties
Recent experimental evidence suggests that in addition to
adhesion molecules, the hepatic sinusoid has other heter-
ogeneous structural and functional properties that create
a unique anatomical vascular bed in which endothelial
lining cells exert antitumor effects with extensive diversity
and flexibility to fight against invading metastatic tumor
cells.
Endothelial-tumor cell interactions induce nitric oxide 
release from the hepatic endothelium
Direct and indirect evidence from the literature has sup-
ported the hypothesis that the hepatic sinusoidal microv-
asculature is toxic to metastatic tumor cells. Various
experimental data obtained to date have indicated that
the hepatic endothelium exerts its antitumor defensive
effects through the release of NO and other reactive oxy-
gen species (ROS) [4,10,15,16,45-47]. As with adhesion
molecule expression, the cytotoxic regulatory functions in
the liver have also been demonstrated to be inducible by
microenvironmental stimuli.
The original evidence that hepatic endothelium-derived
NO is induced by intravascular metastatic tumor cells was
obtained by applying electron paramagnetic resonance
(EPR) NO-spin trapping technologies into a classic
murine melanoma metastatic model [15,48,49]. By inject-
ing fluorescent microsphere-labeled B16F1 melanoma
cells into the portal circulation of C57BL/6 mice, a swift
burst of NO was detected in liver samples within 5 min-
utes of cell injection. NO induced apoptosis in 20–30 %
of the melanoma cells arresting in the liver after 4 h [15].
NO was identified and its cytotoxicity to melanoma cells
was supported by finding that the nonselective NO syn-
thase inhibitor L-NAME (NG-nitro-L-arginine methyl
ester) blocked NO production and melanoma cell apop-
tosis in the sinusoids. The ability of a short burst of NO to
cause apoptosis was further confirmed by detecting the
apoptotic DNA fragmentation and cell membrane dam-
age in B16F1 cells exposed to a NO donor for 5 min in
vitro [15]. The mechanisms of tumor cell specific induc-
tion of NO release at the site of cell arrest have not yet
been identified but are suggested to be partly due to tumor
cell-induced vascular wall shear stress with circumferen-
tial stretch and isometric contraction (Lower levels of NO
are released following injection of inert microspheres with
similar diameters to melanoma cells) [15,50,51]. Using
an in situ liver perfusion system, the cellular origin of the
NO release following B16F1 cell arrest in the liver has
been identified as periportal endothelial and sinusoidal
lining cells, and hepatocytes adjacent to the arrestingComparative Hepatology 2005, 4:8 http://www.comparative-hepatology.com/content/4/1/8
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B16F1 melanoma cell-induced iNOS expression, NO production and nitrotyrosine formation in the mouse liver Figure 1
B16F1 melanoma cell-induced iNOS expression, NO production and nitrotyrosine formation in the mouse 
liver. (A): Induction of hepatic iNOS expression (0–24 h) in various strains of C57BL/6 mice injected with B16F1 melanoma 
cells or polystyrene (P.S.) beads. iNOS was detected by immunofluorescent double-labeling using rabbit anti-mouse iNOS as 
the primary and Cy™3-conjugated goat anti-rabbit IgG as secondary antibodies. Data represent the mean ± SE of iNOS posi-
tive cells in 25 fields of each mouse liver in the group (n = 5 mice/group, at 200 × magnifications). WT: Wild-type. KO: Knock-
out; (B): iNOS expression (orange, arrows) in sinusoidal lining cells and hepatocytes of a wild-type mouse liver at 24 h after 
injection of melanoma cells (green); (C): iNOS detection negative control in a normal wild-type liver without cell injection. (D): 
Liver sample excised immediately after B16F1 cell injection (arrows, 0 h, 100 ×); (E): NO signal detected in the 0 h liver sample 
using EPR spectroscopy; (F): Nitrotyrosine (NT, red, arrows) detection in the same 0 h liver, by double-labeling immunohisto-
chemistry using mouse anti-nitrotyrosine primary antibody, along the sinusoidal wall adjacent and inside the arresting tumor 
cells. (G): A negative control of NT detection in a wild-type mouse liver without tumor cell injection. Scale bars displayed in 
µm.
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B16F1 cells [52]. The endothelial and sinusoidal lining
cells released NO in an eNOS (endothelial NO synthase)-
dependent manner over a time of 500 sec, and hepato-
cytes over a longer period of time measured by fluorescent
4,5-diaminofluorescein diacetate (DAF-2 DA) used as the
NO detection probe [52]. In addition to the immediate
burst of endothelial eNOS-dependent NO production
upon melanoma cell arrest in the liver, a delayed iNOS
(inducible NO synthase)-dependent cytotoxic NO induc-
tion after 4 h of cell injection into the mesenteric vein has
also been demonstrated, which was partially due to the
shear forces generated by melanoma cell arrest in the sinu-
soids, and produced from both sinusoidal lining cells and
hepatocytes detected by double-labeling immunohisto-
chemistry [15] (Figure 1: A – C).
This evidence has been supported by findings from
Umansky et al. [4,16] and Rocha et al. [53]. Using a well-
characterized ESbL-lacZ mouse T lymphoma model, the
authors have shown that a significant increase in NO pro-
duction detected in vitro from  ex vivo isolated liver
endothelial cells and Kupffer cells coincided with the pla-
teau phase (tumor retardation phase) of primary tumor
growth and a low level of liver metastasis. They have also
demonstrated that the activated host liver endothelial
cells play dual roles in metastatic processes by expressing
adhesion molecules and producing NO from iNOS activa-
tion [4,16,53].
Edmiston  et al. have shown that unstimulated murine
sinusoidal endothelial cells produced ROS that were selec-
tively toxic to weakly metastatic human colorectal carci-
noma clone A cells, with the toxicity blockable by
pretreatment with NO synthase inhibitor, superoxide dis-
mutase or dexamethasone [54]. Coculture of ischemic
liver fragments with human colorectal carcinoma cells
killed more weakly metastatic clone A cells at 24 h than
highly metastatic CX-1 cells because of the higher sensitiv-
ity to NO and ROS in clone A cells [47,55]. NO also
induced apoptosis in different human neoplastic lym-
phoid cells and breast cancer cell lines through caspase
activation pathways [46,56].
Endothelial-tumor cell interactions induce release of other 
inducible reactive oxygen species (ROS) from the hepatic 
endothelium
In addition to NO, other cytotoxic ROSs are released from
the liver endothelium and also possess antitumor cytotox-
icity. In vitro, sinusoidal endothelial cells release hydrogen
peroxide (H2O2) which enhanced VLA-4 mediated
melanoma cell adherence to the hepatic sinusoidal
endothelium and caused tumor cytotoxicity after IL-1
treatment in mice [57,58]. Superoxide anion (O2
-) may be
involved in the cytotoxicity of murine hepatic sinusoidal
endothelial cells to weakly metastatic human colorectal
carcinoma cells [47,54,55]. The important interplays
between NO and other ROSs, such as O2
-, in cancer devel-
opment and progression have been reviewed [45]. The
rapid death of most cancer cells after delivery to some tar-
get organs has also been demonstrated to be a conse-
quence of their mechanical interactions within the
microvasculature [12].
The accumulated evidence to date has directed us to rec-
ognize the existence of a host natural defensive mecha-
nism network in the hepatic microvasculature through the
production of NO and other ROSs from the sinusoidal
endothelium to generate cytotoxicity to invading intravas-
cular tumor cells to fight against cancer metastasis in the
liver.
Impact of sinusoidal structural and functional 
characteristics on nitric oxide induction
Similar to the inducible adhesion molecule expression
under the influence of hepatic zonal heterogeneity, evi-
dence suggests that the release of NO from the hepatic
endothelium is restricted to specific anatomical zones.
Using an in situ C57BL/6 mouse liver perfusion system,
the levels of NO production without and with tumor cells
in the liver were found to be much greater in acinar zone
1 than zone 2 and 3 by direct visualization of NO synthe-
sis through deesterification and conversion of intracellu-
lar DAF-2 DA to DAF-2T [52]. In cirrhotic mouse livers
with altered sinusoidal architecture, significantly lower
levels of NO production were detected both under basal
conditions (without tumor cells) and after tumor cell
arrest by the same experimental system [44].
Evidence of cytotoxic properties in extrahepatic 
microvascular beds
The detection of a host defensive mechanism existing in
the hepatic endothelium has raised the question of
whether similar defense mechanisms also exist in other
metastatic target organs. Direct in vitro lysis of metastatic
tumor cells by cytokine-activated murine lung vascular
endothelial cells has been demonstrated. NO (detected by
nitrite concentration in the culture medium) produced by
interferon gamma and TNF-activated lung vascular
endothelial cells played a major role in the lytic destruc-
tion of reticulum cell sarcoma [59,60]. Rapid death of
transformed metastatic rat embryo cells, occurred via
apoptosis in the lungs 24–48 h after injection into the cir-
culation of immune-deficient nu/nu mice, has been
reported [14,61].
Using EPR NO-spin trapping technologies, a significantly
increased production of NO was detected in lung tissue
samples between 20 min and 4 h after the tail vein injec-
tion of fluorescent microsphere-labeled B16F1 melanoma
cells [49]. The EPR results were also supported in an iso-Comparative Hepatology 2005, 4:8 http://www.comparative-hepatology.com/content/4/1/8
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lated, ventilated and blood-free mouse lung perfusion
model, where NO production in situ was observed in real
time using intact organ microscopy techniques. Fluores-
cent NO signals (DAF-2T) increased rapidly at the site of
tumor cell arrest in the lungs and continued to increase
throughout 20 min thereafter [49,62]. NO contributed to
tumor cell apoptosis since 3-fold more B16F1 cells subse-
quently underwent apoptosis in the lungs of wild-type
mice compared to animals in which NO production was
inhibited, in particular, in eNOS-deficient mice and NOS
inhibitor L-NAME-pretreated mice [49].
The identification of a similar antitumor defensive mech-
anism in the pulmonary microvascular bed has reinforced
the concept that the host can release NO and other ROSs
as cytotoxic effector molecules to fight against the invad-
ing metastatic tumor cells in the microvascular beds of the
first-line cancer metastatic organs, such as the liver and
lung.
Molecular mechanisms of nitric oxide-induced melanoma 
cell cytotoxicity
The majority of reports indicate that the underlying
molecular mechanisms for NO-induced tumor cell cyto-
toxicity are direct damage to DNA and the cell membrane,
or activation of apoptosis-initiating caspases (cysteine
proteases) causing tumor cell apoptosis and necrosis
[10,14,15,45-47,49,54,56,59,60]. In addition, prelimi-
nary evidence also suggests that NO may induce oxidative
damage on proteins through NO-superoxide-peroxyni-
trite and NO-nitrogen dioxide-nitrite pathways to form
nitrotyrosine. The latter is the footprint of potent short-
lived reactive nitrogen species, peroxynitrite (ONOO-)
production  in vivo, mediating NO-induced oxidative
attacks on biological macromolecules [63-65] (Figure 1:
D–G). More observations need to be made to provide sup-
portive evidence along this direction.
Interactions between nitric oxide and adhesion molecules 
in the hepatic microvascular bed
The importance of interplays between NO and adhesion
molecules in the regulation of liver cancer metastasis has
been recognized and addressed in recent years
[10,19,20,45]. The inducible murine hepatic microvascu-
lar adhesive and cytotoxic regulatory functions have been
regulated by using LPS [28,30]. With enhanced local
expression of VCAM-1 and ICAM-1 around B16F1 cell
arrest sites in the liver, LPS significantly increased the
retention of melanoma cells in the liver, especially in the
terminal portal venule regions between 8 and 24 h after
intramesenteric injection of melanoma cells [30]. LPS also
significantly increased the levels of iNOS expression and
tumor cell induced-NO production at 8 h after adminis-
tration and cell injection, and increased the rates of B16F1
cell apoptosis in the terminal portal venule region [30].
These data have been interpreted to indicate that LPS stim-
ulated a synergistic interaction by inducing both the
hepatic endothelial adhesion molecule expression and
NO release in the terminal portal venular regions, result-
ing in higher levels of tumor cell killing in this region in
the liver [30]. The dual roles of activated host liver
endothelial cells in murine lymphoma metastatic process
have also been reviewed [16]. On one hand, upregulation
of the expression of particular adhesion molecules is con-
sidered to lead to the increased tumor cell binding and
stimulation of angiogenesis, and on the other hand,
endothelial cells can contribute to host anti-metastatic
responses by producing the cytotoxic molecule NO from
arginine with the help of iNOS [16]. Synergistic interac-
tions between LFA-1/ICAM-1 and lymphoma progression
phases with cytotoxic NO production have been described
[4]. Interactions between cytokine IL-18, VCAM-1, H2O2
and hepatic sinusoidal endothelial cells have also been
demonstrated [35]. Recombinant catalase administered in
vivo completely blocked the increase of VCAM-1 expres-
sion induced by B16M cell arrest in the liver, and blocked
in vitro B16M cell adhesion to sinusoidal lining cells iso-
lated from B16M cell-injected mice [35]. Incubation of
hepatic endothelial cells with nontoxic concentrations of
H2O2 directly enhanced VCAM-1-dependent B16M cell
adhesion  in vitro without proinflammatory cytokine
mediation [35].
In addition to synergistic interactions between NO and
adhesion molecules, their counteractive interactions have
also been identified. NO reduces tumor cell adhesion to
isolated rat postcapillary venules in vitro [66]. Anti-adhe-
sive roles of constitutively produced NO in inhibiting leu-
kocyte rolling and adhesion in the microcirculation have
been described [67,68]. Oxidative stress in the liver can be
caused by ischemia/reperfusion (I/R) injury when tumor
cells entering the hepatic microcirculation obstruct
hepatic sinusoids and temporarily occlude blood flow
before the hepatic circulation is reestablished by either
tumor cell death or invasion into the parenchyma [8,55].
The counteractive roles of NO with adhesion molecules,
such as decreasing P-selectin and ICAM-1 mRNA expres-
sion, attenuating neutrophil accumulation and liver dam-
age in hepatic ischemia/reperfusion injury have been
reviewed [69-71]. IL-10 has also been shown to inhibit
hepatic I/R injury by inhibiting the upregulation of iNOS
expression following I/R injury [55]. The multifaceted
roles and effects of NO and adhesion molecule interac-
tions support the scenario that the host uses this flexible
natural defensive mechanism to protect itself from a vari-
ety of disastrous oxidative injuries and tissue damages to
the hepatic microvasculature.Comparative Hepatology 2005, 4:8 http://www.comparative-hepatology.com/content/4/1/8
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Effects of sinusoidal adhesive and cytotoxic 
functions on metastasis
Substantial experimental evidence supports the hypothe-
sis that hepatic adhesive functions can regulate cancer
metastatic outcomes in the liver. IL-1α pretreated mice
had 11-22-fold greater hepatic melanoma tumor burden
than control mice pretreated with saline presumably
through altering adhesive interactions between B16F1
cells and the hepatic microvasculature [24,72]. Liver sec-
tions from IL-1α-pretreated mice attracted 3-fold more
melanoma cells to adhere in vitro than control liver sec-
tions. Adhesion was blocked by antibodies to E-selectin,
ICAM-1, VCAM-1 and αv integrin subunit [24]. A single
dose of IL-1 receptor antagonist (0.2 mg/kg, i.p.) given 2
h before intrasplenic injection of melanoma cells reduced
the number of hepatic metastases by 50% and metastatic
volume by 70% compared with the vehicle-injected con-
trol mice [73]. Systemic inflammation induced by intrave-
nous injection of IL-1 or LPS increased hepatic melanoma
metastasis significantly in an IL-1 dependent manner
[74]. E-selectin expression blockage by monoclonal anti-
body significantly reduced experimental liver metastasis
in the mouse [21]. Blockade of VCAM-1 expression in vivo
with specific antibodies, administered before B16M cell
injection into the portal circulation, decreased sinusoidal
retention of luciferase-transfected B16M cells by 85%, and
metastasis development by 75%, indicating that VCAM-1
expression on tumor-activated sinusoidal endothelial
cells had a prometastatic contribution [35].
In addition to such adhesive functions, hepatic cytotoxic
properties alone or through interactions with adhesive
Modified classic metastatic cascade Figure 2
Modified classic metastatic cascade. Traditional metastatic cascade: Steps a → b → c → d → e, → g → h → i → j. Modi-
fied metastatic cascade: Steps a → b → c → d → e → f → g → h → i → j, with a new "f" step of passing through endothelial 
defense mechanisms included.
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function and hepatic vascular zonal heterogeneity have
been demonstrated to contribute significantly to the inhi-
bition of tumor growth in the secondary sites. With 2/3 of
intramesenteric injected-B16F1 cells arresting in the liver
sinusoids, the rapid burst of NO induction triggered
apoptosis in 1/4 of the intravascular melanoma cells and
significantly decreased the metastatic tumor burden in the
liver [15]. Increased NO production by ex vivo isolated
liver sinusoidal endothelial cells was detected in the
tumor growth retardation phase in a well-characterized
murine T lymphoma model, and the breakdown of this
NO synthesis coincided with the second tumor expansion
phase [4,16,53]. LPS has been demonstrated to inhibit
melanoma metastases formation in the liver by inducing
NO release and adhesion molecule expression in the
hepatic endothelium, which was primarily located within
the terminal portal venular region (acinar zone 1) [30].
Selective implantation and growth in rats and mice of
experimental liver metastasis in acinar zone 1 has been
demonstrated using B16 melanoma and Lewis lung carci-
noma cell lines [75]. Cirrhotic livers with narrowed sinu-
soidal lumens were found to have decreased velocity of
melanoma cell traveling in the sinusoids, decreased NO
release and tumor cell apoptosis, and increased tumor cell
proliferation and metastases formation in the liver [44].
The vascular-targeting agent ZD6126 was able to reduce
the liver metastatic burden significantly in mice with
extensive tumor necrosis, increased tumor cell apoptosis
and a reduction in tumor-associated vasculature with dis-
rupted and non-functional vascular channels within
metastases with no blood flow [76]. In the pulmonary
vascular bed, NO production following tail vein injection
of B16F1 melanoma cells induced 3-fold higher apoptosis
rate, 30 % higher tumor cell clearance, and 2 to 5-fold less
metastases formation in wild-type mice in comparison
with the controls [49].
Given the functional and structural features (adhesion,
cytotoxicity, zonal differentiation) of the hepatic microv-
asculature, and the fact that the liver and lung are the most
common metastatic target organs, the ability of their vas-
culatures to produce cytotoxic molecules is of considera-
ble interest as a means to protect the host from circulating
metastatic cells. The presence of a tumor-killing defensive
mechanism in the liver and lungs provides an additional
explanation for tumor cell loss in these secondary organs
and helps to explain the inefficient process of cancer
metastasis.
Cancer metastatic cascade modified
The compelling data elaborated above on regulations of
liver cancer metastasis by the hepatic microvascular adhe-
sive and cytotoxic functions prompted us to review the
classic metastatic cascade again, which includes the pri-
mary tumor cell local invasion, intravasation, circulation,
adhesion and extravasation, survival and proliferation in
the secondary organ [3,4,8,22,77]. A new step in which
tumor cells pass through the host endothelial defensive
mechanisms has been incorporated into the traditional
model (Figure 2).
Conclusion
In summary, there is convincing evidence that hepatic
endothelial adhesive and cytotoxic properties can signifi-
cantly influence the interactions between metastatic
tumor cells and the liver with a consequence of altering
the formation of liver metastases. In addition, the hepatic
endothelial adhesive and cytotoxic functions are induci-
ble, zonal, heterogeneous, affected by sinusoidal struc-
tural alterations, and can interact with each other
synergistically or counteractively. Together they provide
the liver with a specific vascular bed with extensive diver-
sity and flexibility to fight against invading metastatic
tumor cells and other tissue injuries. A similar inducible
antitumor defensive mechanism also exists in the pulmo-
nary microvascular bed. The molecular mechanisms of
the hepatic endothelial cytotoxicity are beginning to be
identified. Production of NO and other ROSs from the
sinusoidal endothelium causes damage to tumor cell
DNA, cell membrane, and protein macromolecules. This
natural defensive mechanism in the hepatic and pulmo-
nary microvasculature contributes to our understanding
of tumor cell loss in the secondary organ, helps to explain
cancer metastatic inefficiency, and is an additional barrier
to metastasis in the classic model of the cancer metastatic
cascade.
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